Serina Therapeutics Inc./$SER
1D1W1MYTD1Y5YMAX
Capital at risk
About Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
- Ticker
- $SER
- Sector
- Health
- Primary listing
- AMEX
- Employees
- -
- Headquarters
- Huntsville, United States
- Website
- serinatherapeutics.com
SER Metrics
BasicAdvanced
$57M
-
-$1.93
-
-
Price and volume
Market cap
$57M
52-week high
$5.83
52-week low
$1.22
Average daily volume
68K
Financial strength
Current ratio
6.653
Quick ratio
6.12
Long term debt to equity
0.171
Total debt to equity
0.2
Interest coverage (TTM)
-43.06%
Profitability
EBITDA (TTM)
-25.587
Effective tax rate (TTM)
-0.09%
Management effectiveness
Return on assets (TTM)
-92.30%
Return on equity (TTM)
-207.94%
Valuation
Price to book
3.05
Price to tangible book (TTM)
3.05
Price to free cash flow (TTM)
-1.312
Free cash flow yield (TTM)
-76.21%
Free cash flow per share (TTM)
-1.715
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
44.26%
3-year earnings per share growth (CAGR)
93.60%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.